Home / Multidrug Transporter Inhibitors / Ko 143

Ko 143

Catalog #: 3241
13 Citations Datasheet
Catalog # Availability Size / Price Qty
3241/1
3241/10
Ko 143 | CAS No. 461054-93-3 | Multidrug Transporter Inhibitors
1 Image
Description: Potent and selective BCRP inhibitor

Chemical Name: (3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester

Purity: ≥99%

Product Details
Citations (13)
Supplemental Products
Reviews
Biological Activity Technical Data Background Product Datasheets Calculators

Biological Activity

Ko 143 is a potent and selective breast cancer resistance protein multidrug transporter (BCRP) inhibitor (EC90 = 26 nM). Displays > 200-fold selectivity over P-gp and MRP-1 transporters. Increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance. Inhibits ABCB1 and ABCC1 at higher concentrations. Rapidly metabolized in rat plasma.

Technical Data

M.Wt:
469.57
Formula:
C26H35N3O5
Solubility:
Soluble to 50 mM in DMSO and to 100 mM in ethanol
Purity:
≥99%
Storage:
Store at -20°C
CAS No:
461054-93-3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

  1. Barrier properties and transcriptome expression in human iPSC-derived models of the blood-brain barrier
    L Delsing, P Dönnes, J Sánchez, M Clausen, D Voulgaris, A Falk, A Herland, G Brolén, H Zetterberg, R Hicks, J Synnergren
    Stem Cells, 2018;0(0):.
  2. ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
    Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel Y, Fatima S, Kawauchi D, Shelat A, Stewart C, Sorrentino B, Schuetz J, Roussel M
    Cancer Res, 2015;75(18):3879-89.
  3. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
    Zander, Serge A, Sol, Wendy, Greenberger, Lee, Zhang, Yixian, van Tellingen, Olaf, Jonkers, Jos, Borst, Piet, Rottenberg, Sven
    PLoS ONE, 2012;7(9):e45248.
  4. PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter.
    Hegedus C, Truta-Feles K, Antalffy G, Brozik A, Kasza I, Nemet K, Orban TI, Ozvegy-Laczka C, Varadi A, Sarkadi B
    Biochem. Biophys. Res. Commun., 2012;420(4):869-74.
  5. E2F1 drives chemotherapeutic drug resistance via ABCG2.
    Rosenfeldt M, Bell L, Long J, O'Prey J, Nixon C, Roberts F, Dufes C, Ryan K
    Oncogene, 2014;33(32):4164-72.
  6. The inhibitor Ko143 is not specific for ABCG2.
    Weidner et al.
    J.Pharmacol.Exp.Ther., 2015;354:384
  7. Potent and specific inhibition of breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
    Allen et al.
    Mol.Cancer Ther., 2002;1:417
  8. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etop. resistance and transport, but etop. oral availability is limited primarily by P-glycoprotein.
    Allen et al.
    Cancer Res., 2003;63:1339

Product Datasheets

COA view current batch
Or select another batch:
View Batch
SDS

Citations for Ko 143

The citations listed below are publications that use Tocris products. Selected citations for Ko 143 include:

13 Citations: Showing 1 - 10

  1. IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process.
    Authors: Coz Et al.
    Oncotarget  2016;7:82511
  2. Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.
    Authors: Kumar Et al.
    Sci Rep  2016;6:20418
  3. A role for ABCG2 beyond drug transport: Regulation of autophagy.
    Authors: Ding Et al.
    Autophagy  2016;12:737
  4. ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
    Authors: Morfouace Et al.
    Cancer Res  2015;75:3879
  5. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
    Authors: Hoque Et al.
    Biochem Pharmacol  2015;59:2572
  6. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irino. in colon and lung cancer models with ABCG2-induced resistance.
    Authors: Westover Et al.
    Brain Res  2015;14:92
  7. Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.
    Authors: Moreno-Sanz Et al.
    Pharmacol Res  2014;87:87
  8. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
    Authors: Hill Et al.
    J Biol Chem  2013;85:29
  9. Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
    Authors: Moreno-Sanz Et al.
    J Med Chem  2013;56:5917
  10. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topo. resistance in BRCA1-deficient mouse mammary tumors.
    Authors: Zander Et al.
    PLoS One  2012;7:e45248

FAQs

No product specific FAQs exist for this product, however you may

View all Small Molecule FAQs

Reviews for Ko 143

There are currently no reviews for this product. Be the first to review Ko 143 and earn rewards!

Have you used Ko 143?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review
Tocris Bioscience is the leading supplier of novel and exclusive tools for life science research with over 30 years' experience in the industry. Tocris is a Bio-Techne brand.